ArticleBritish journal of pharmacology1994
Routes of delivery of muscarinic acetylcholine receptors to the plasma membrane in NG108-15 cells.
Article in British journal of pharmacology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 15 citations in OpenAlex.
- Comparison of the kinetics and extent of muscarinic M1-M5 receptor internalization, recycling and downregulation in Chinese hamster ovary cells.European journal of pharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. We have examined the routes of delivery of muscarinic acetylcholine receptors to the plasma membrane in unstimulated and agonist-stimulated NG108-15 cells. Delivery of receptors to the plasma membrane was measured by irreversible alkylating receptors already at the cell surface with propylbenzilylcholine mustard (PrBCM) and then following the recovery of binding of the polar radioligand [3H]-N-methylscopolamine ([3H]-NMS) in intact cells. 2. In unstimulated cells, recovery of [3H]-NMS binding after 2 h of incubation at 37 degrees C was 30% of binding in control cells. Binding affinity of [3H]-NMS was unchanged. In cells that had been pre-exposed to carbachol (0.5 mM) for 30 min, initial [3H]-NMS binding was reduced by 38% but recovery of binding was increased from 30% to 43% of control binding. 3. When the cells were pre-incubated for 1 h with the protein synthesis inhibitor cycloheximide (20 micrograms ml-1), recovery of [3H]-NMS binding was reduced by similar extents in unstimulated (30% to 9%) and carbachol-stimulated (43% to 19%) cells. Incubation of the cells at 20 degrees C instead of 37 degrees C reduced recovery of [3H]-NMS binding from 30% to 9% in unstimulated cells and from 43% to 23% in carbachol-stimulated cells. 4. Depletion of cellular ATP by addition of antimycin (50 nM) and deoxyglucose (50 mM), reduced recovery of binding to 12% in unstimulated cells and to 6% in carbachol-stimulated cells. 5. These results indicate that in unstimulated NG108-15 cells, delivery of muscarinic receptors to the plasma membrane is almost exclusively through the synthetic pathway. In agonist-stimulated cells,receptor sequestration into an intracellular compartment (probably endosomes) occurs. Under these circumstances, delivery of receptors to the plasma membrane along the synthetic route is unaffected but an additional route of delivery (recycling) now operates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.